Cargando…
Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval
PURPOSE: Wilms tumor 1 (WT1) gene has recently shown a role in gliomagenesis, making it a potential immunotherapy target in glioblastomas. We aimed to investigate the most sensitive method to detect WT1 expression in glioblastoma and explore the relationship between WT1 expression, IDH1 mutation and...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318730/ https://www.ncbi.nlm.nih.gov/pubmed/34335021 http://dx.doi.org/10.2147/BTT.S323358 |
_version_ | 1783730304587923456 |
---|---|
author | Kurdi, Maher Butt, Nadeem Shafique Baeesa, Saleh Kuerban, Abudukadeer Maghrabi, Yazid Bardeesi, Anas Saeedi, Rothaina Alghamdi, Badrah S Lary, Ahmed I Mohamed, Fawaz Hakamy, Sahar |
author_facet | Kurdi, Maher Butt, Nadeem Shafique Baeesa, Saleh Kuerban, Abudukadeer Maghrabi, Yazid Bardeesi, Anas Saeedi, Rothaina Alghamdi, Badrah S Lary, Ahmed I Mohamed, Fawaz Hakamy, Sahar |
author_sort | Kurdi, Maher |
collection | PubMed |
description | PURPOSE: Wilms tumor 1 (WT1) gene has recently shown a role in gliomagenesis, making it a potential immunotherapy target in glioblastomas. We aimed to investigate the most sensitive method to detect WT1 expression in glioblastoma and explore the relationship between WT1 expression, IDH1 mutation and recurrence interval. PATIENTS AND METHODS: Clinical data were collected from 44 patients with glioblastomas, treated with adjuvant therapies. WT1 expression was assessed in all cases using immunohistochemistry (IHC), while its gene expression was assessed in 13 clustered samples using polymerase chain reaction (qPCR). IDH1 mutation was assessed using IHC. The sensitivity between IHC and RT-qPCR was examined. Kaplan–Meier curves were used to compare the recurrence-free interval (RFI) between IDH1 and WT1 expression groups. RESULTS: IDH1(wildtype) was found in 26 cases (59.1%) and the remaining 18 cases (40.9%) were IDH1(mutant). Through IHC, WT1 was overexpressed in 32 cases (72.7%), partially expressed in 9 cases (20.5%) and not expressed in only 3 cases. For the 13 cases tested by qPCR, 6 cases showed WT1 upregulation and 7 cases showed WT1 downregulation. There was no significant difference in WT1 expression among cases with different RNA concentrations regardless the testing method (p-value >0.05). However, the difference between IHC and qPCR was significant. IDH1(mutant) cases with WT1 overexpression showed significant difference in RFI (p-value =0.048). CONCLUSION: Parallel testing for WT1 expression using IHC and qPCR is not reliable. However, IHC provides more accurate results. Moreover, IDH1(mutant) glioblastomas with WT1 overexpression are associated with late RFI particularly if temozolomide with additional chemotherapies are used. |
format | Online Article Text |
id | pubmed-8318730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-83187302021-07-30 Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval Kurdi, Maher Butt, Nadeem Shafique Baeesa, Saleh Kuerban, Abudukadeer Maghrabi, Yazid Bardeesi, Anas Saeedi, Rothaina Alghamdi, Badrah S Lary, Ahmed I Mohamed, Fawaz Hakamy, Sahar Biologics Original Research PURPOSE: Wilms tumor 1 (WT1) gene has recently shown a role in gliomagenesis, making it a potential immunotherapy target in glioblastomas. We aimed to investigate the most sensitive method to detect WT1 expression in glioblastoma and explore the relationship between WT1 expression, IDH1 mutation and recurrence interval. PATIENTS AND METHODS: Clinical data were collected from 44 patients with glioblastomas, treated with adjuvant therapies. WT1 expression was assessed in all cases using immunohistochemistry (IHC), while its gene expression was assessed in 13 clustered samples using polymerase chain reaction (qPCR). IDH1 mutation was assessed using IHC. The sensitivity between IHC and RT-qPCR was examined. Kaplan–Meier curves were used to compare the recurrence-free interval (RFI) between IDH1 and WT1 expression groups. RESULTS: IDH1(wildtype) was found in 26 cases (59.1%) and the remaining 18 cases (40.9%) were IDH1(mutant). Through IHC, WT1 was overexpressed in 32 cases (72.7%), partially expressed in 9 cases (20.5%) and not expressed in only 3 cases. For the 13 cases tested by qPCR, 6 cases showed WT1 upregulation and 7 cases showed WT1 downregulation. There was no significant difference in WT1 expression among cases with different RNA concentrations regardless the testing method (p-value >0.05). However, the difference between IHC and qPCR was significant. IDH1(mutant) cases with WT1 overexpression showed significant difference in RFI (p-value =0.048). CONCLUSION: Parallel testing for WT1 expression using IHC and qPCR is not reliable. However, IHC provides more accurate results. Moreover, IDH1(mutant) glioblastomas with WT1 overexpression are associated with late RFI particularly if temozolomide with additional chemotherapies are used. Dove 2021-07-24 /pmc/articles/PMC8318730/ /pubmed/34335021 http://dx.doi.org/10.2147/BTT.S323358 Text en © 2021 Kurdi et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Kurdi, Maher Butt, Nadeem Shafique Baeesa, Saleh Kuerban, Abudukadeer Maghrabi, Yazid Bardeesi, Anas Saeedi, Rothaina Alghamdi, Badrah S Lary, Ahmed I Mohamed, Fawaz Hakamy, Sahar Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval |
title | Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval |
title_full | Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval |
title_fullStr | Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval |
title_full_unstemmed | Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval |
title_short | Sensitivity Assessment of Wilms Tumor Gene (WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval |
title_sort | sensitivity assessment of wilms tumor gene (wt1) expression in glioblastoma using qpcr and immunohistochemistry and its association with idh1 mutation and recurrence interval |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318730/ https://www.ncbi.nlm.nih.gov/pubmed/34335021 http://dx.doi.org/10.2147/BTT.S323358 |
work_keys_str_mv | AT kurdimaher sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT buttnadeemshafique sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT baeesasaleh sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT kuerbanabudukadeer sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT maghrabiyazid sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT bardeesianas sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT saeedirothaina sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT alghamdibadrahs sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT laryahmedi sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT mohamedfawaz sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval AT hakamysahar sensitivityassessmentofwilmstumorgenewt1expressioninglioblastomausingqpcrandimmunohistochemistryanditsassociationwithidh1mutationandrecurrenceinterval |